Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 6/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.32 |
| ▸ | TSHR | P16473 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | FAAH | O00519 | 1/20 | 0.30 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.30 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17837301 | 0.90 | CA1 (0.39) | CYP2C19KMT2AMEN1CYP2D6CYP3A4 | |
| SCHEMBL17837267 | 0.90 | CYP3A4 (0.39) | CYP2C19KMT2AMEN1CYP2D6CYP3A4 | |
| SCHEMBL17837292 | 0.78 | CYP3A4 (0.39) | CYP2C19CYP3A4TSHRALDH1A1CYP2C9 | |
| SCHEMBL17837304 | 0.77 | CYP2C19 (0.32) | CYP2C19CYP3A4TSHRALDH1A1CYP2C9 | |
| SCHEMBL17837309 | 0.76 | FAAH (0.36) | KMT2ATSHRALDH1A1POLBMAPK1 | |
| SCHEMBL17837312 | 0.74 | CYP2C19 (0.35) | CYP2C19KMT2AMEN1CYP2D6CYP3A4 | |
| SCHEMBL17854733 | 0.67 | FAAH (0.38) | CYP2C19KMT2ATSHRPOLBFAAH | |
| SCHEMBL17837303 | 0.65 | FAAH (0.38) | KMT2AMEN1TSHRALDH1A1CYP2C9 | |
| SCHEMBL14498565 | 0.65 | ALDH1A1 (0.33) | CYP3A4TSHRALDH1A1POLB | |
| SCHEMBL17837269 | 0.65 | FAAH (0.38) | CYP3A4ALDH1A1FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11377396-B2 | Enantioselective synthesis of α-quaternary Mannich adducts by palladium-catalyzed allylic alkylation | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2022-07-05 | — | — | US | disclosed |
| US-20200157020-A1 | ENANTIOSELECTIVE SYNTHESIS OF ALPHA-QUATERNARY MANNICH ADDUCTS BY PALLADIUM-CATALYZED ALLYLIC ALKYLATION | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2020-05-21 | — | — | US | disclosed |
| US-10421696-B2 | Enantioselective synthesis of α-quaternary mannich adducts by palladium-catalyzed allylic alkylation | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2019-09-24 | — | — | US | disclosed |
| US-20160176773-A1 | ENANTIOSELECTIVE SYNTHESIS OF alpha-QUATERNARY MANNICH ADDUCTS BY PALLADIUM-CATALYZED ALLYLIC ALKYLATION | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2016-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11377396-B2 | Enantioselective synthesis of α-quaternary Mannich adducts by palladium-catalyzed allylic alkylation | ALG8, MANBA, MAN2A1 | CYP2C19 492/4885KMT2A 214/4885MEN1 117/4885 |
| US-10421696-B2 | Enantioselective synthesis of α-quaternary mannich adducts by palladium-catalyzed allylic alkylation | ALG8, MANBA, MAN2A1 | CYP2C19 492/4885KMT2A 214/4885MEN1 117/4885 |
| US-20160176773-A1 | ENANTIOSELECTIVE SYNTHESIS OF alpha-QUATERNARY MANNICH ADDUCTS BY PALLADIUM-CATALYZED ALLYLIC ALKYLATION | ALG8, MANBA, MAN2A1 | CYP2C19 651/4885KMT2A 245/4885MEN1 92/4885 |
| US-20200157020-A1 | ENANTIOSELECTIVE SYNTHESIS OF ALPHA-QUATERNARY MANNICH ADDUCTS BY PALLADIUM-CATALYZED ALLYLIC ALKYLATION | ALG8, MANBA, MAN2A1 | CYP2C19 651/4885KMT2A 245/4885MEN1 92/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.